Radically Simplifying Stem Cell Product Development | Jon Rowley | Maryland Stem Cell Research Fund

RoosterBio's stem cell products radically simplify regenerative medicine drug development. In this video, RoosterBio Founder Dr. Jon Rowley shares how the company is industrializing the regenerative medicine supply chain with a set of unique products that radically simplify the incorporation of living stem cells into tomorrow's regenerative drugs.
RoosterBio is an emerging regenerative medicine manufacturing technology company. Its manufacturing is ripe for standardization and disruption in healthcare as the company enables researchers to accelerate their development of regenerative medicine therapies, including stem cell therapy, gene therapy, and cellular therapy. The Maryland Stem Cell Research Fund (MSCRF) was one of the first to fund the company to expand its product line.
Having had close to 20 years of experience in manufacturing process development, Rowley realized in the late 2000s that almost every company was having the same challenge progressing therapies into clinical trials due to the inability to grow stem cell banks. He realized he could help them accelerate their development process by standardizing and providing them MSC cell banks to begin work.
MSC stands for mesenchymal stem or mesenchymal stromal cell. Rowley thinks of these mesenchymal stem cells as tissue regeneration repair cells. MSCs are used in clinical research to cause a positive immune system response in the human body across a range of indications from neurological disorders to cardiac regeneration, orthopedics, kidney failure, and wound healing.
Rowley accurately understood the field of regenerative medicine was growing and Rooster Bios products took off. The company started with 5-7 employees in 2013 and is now at 50 employees in 2021. Rowley's ability to scale and meet market demand would not have been possible without the investments by The Maryland Stem Cell Research Fund, which helped RoosterBio launch two new products in less than three years.
The Sky Is The Limit
In the next few years, RoosterBio expects to be a global company, supplying MSCs around the world with a global supply chain distribution network that supports therapeutic development across North America, Europe, Asia, and the Pacific. RoosterBio also plans to begin applying its model to other biological raw materials that are needed within regenerative medicine.
Rowley shares in this video, "our goal is to have the same impact on the regenerative medicine industry that Intel had on the personal computer industry, where having standardized off the shelf technology components radically changes the dynamics of product development and commercialization of high-tech products, whether it be computers or living cell-based, regenerative medicines."
This expansion to be a one-stop-shop for everything MSCs and to standardize the supply chain in a fragmented industry has tremendous market value for Maryland and the United States--with over 300 MSC clinical trials, globally, initiated last year, the MSC market is estimated to be between $1.5 - $2 billion.
The Maryland Stem Cell Research Fund is honoring its mission of "Accelerating Cures" by investing in RoosterBio. Interested in having your research funded by the Maryland Stem Cell Research Fund? Apply now: www.mscrf.org/...
------------
About the Maryland Stem Cell Research Fund: www.mscrf.org/
Interested in collaborating with us? Reach out to Dr. Amritha Jaishankar, Executive Director, MSCRF: / amrithajaishankar
Or, follow us on LinkedIn or Twitter to learn about opportunities:
LinkedIn: / about
Twitter: / md_stem_cell
#regenerativemedicine #celltherapy #cellandgenetherapy